

FOR ALZHEIMER'S PATIENTS

There is
Something
You Can Do.



For yourself & for others.

*Why take part in a
clinical study?*

Clinical trials serve as the bridge between laboratory science and the medicines we get at the pharmacy. They are an essential part of efforts to ensure the safety and effectiveness of new medical treatments. The Food and Drug Administration (FDA) requires the successful completion of clinical trials before a medication can be approved for use in people.

*The Aladdin study
offers an investigational
drug that could improve
the treatment of
Alzheimer's patients.*




ALADDIN
The Alzheimer's Study

*By taking part in a clinical trial,
you can help to make new
treatments possible, and play a part
in supporting medical research.*


ALADDIN
The Alzheimer's Study

Why take part in a clinical study?

Clinical trials serve as the bridge between laboratory science and the medicines we get at the pharmacy. They are an essential part of efforts to ensure the safety and effectiveness of new medical treatments. The Food and Drug Administration (FDA) requires the successful completion of clinical trials before a medication can be approved for use in people.



By taking part in a clinical trial, you can help to make new treatments possible, and play a part in supporting medical research.

What is the Aladdin study?

The Aladdin study is a research program designed to investigate the ability of a drug called leuprolide to slow the progression of Alzheimer's disease. Leuprolide is currently approved to treat other conditions, but has not been approved by the FDA to treat Alzheimer's disease.

How does it work?

You will undergo an initial screening by a study doctor. If you qualify, you will either receive the active medication or a placebo (a non-active substance), once every eight weeks for 48 weeks. You will be seen approximately every 8 weeks for up to 56 weeks. During most of those visits, tests of memory and thinking, as well as overall functioning and behavior will be conducted.

Several initial studies have already been conducted. Based on the results of these studies, we are actively recruiting patients to take part in a new phase.

Although there may be no direct benefit to you in participating in this study, your participation will help us gain more knowledge about Alzheimer's disease.

All expenses associated with being in this study will be at no cost to you.

Who can participate in the study?

*People 65 years and older
with mild to moderate
Alzheimer's disease*

&

*have been taking Aricept®, Exelon™,
Razadyne® (formerly Reminyl), or
Cognex® for at least 4 months*

Aricept® is a registered trademark of Eisai, Inc and Pfizer. Razadyne™ is a trademark & marketed by Ortho-McNeil Neurologics, Inc. Exelon® is a registered trademark of Novartis Pharmaceuticals Corporation.